Ractigen

Ractigen is a startup pharmaceutical company dedicated to the development of innovative drugs and disease treatments centered around "RNA activation" technology. RNA activation (RNAa) is currently the only disruptive technology capable of achieving endogenous gene activation and has entered clinical validation. By reactivating the expression of endogenous genes and restoring the natural function of proteins, RNAa has the potential to fill a significant gap left by existing targeted therapies that can only inhibit target gene and protein expression. Founded in 2016 in Jiangsu, China, by pioneers in the field of RNA activation, Ractigen is developing drug candidates across multiple disease areas to address highly unmet clinical needs.